Arcutis (ARQT) Q3 2026 Earnings Call Transcript

Arcutis Biotherapeutics (ARQT) reported Q3 2026 revenue of $143.9M, up 45% YoY, driven by ZORYVE franchise growth. Full-year revenue guidance raised to $535M-$545M. Net income was $8.8M, with cash and securities at $259.8M. The company plans to invest in commercial initiatives for 2027 growth, focusing on dermatology and primary care.

Original reporting
Published Nov 5, 2026, 4:42 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 5:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Arcutis (ARQT) Q3 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$ARQTBullishMed
01

Why it matters

The earnings beat and guidance raise provide a fresh catalyst for short‑term price movement; longer‑term risk remains tied to clinical trial outcomes.

02

Market read

First‑time earnings release with upward guidance for a small‑cap biotech; actionable for traders monitoring biotech earnings beats.

03

What to watch

Higher SG&A spend and upcoming PDUFA dates could pressure cash flow later in 2027.

Relevance 7/10Novelty 7/10Timing: after-hours release

Background

Arcutis Biotherapeutics (NASDAQ:ARQT) is a specialty dermatology biotech focused on non‑steroidal topical treatments.

Company-level read

Ticker impact

$ARQTBullishHigh confidence
Context

Arcutis reported Q3 2026 results with $143.9M revenue and raised full-year guidance to $535‑$545M, a fresh earnings disclosure.

Expected impact

likely modest upside as market prices in higher guidance

Evidence & confidence

Revenue up 45% YoY and guidance raised above prior range; investors may bid the stock higher.

Market effects

Positive for dermatology biotech sector as ZORYVE franchise shows strong demand.

US biotech market may see modest lift.

Limited to investors tracking small‑cap biotech earnings.

Counterpoint

Guidance raise may already be priced in; execution risk on upcoming trials could temper upside.

Key entities

  • Frank Watanabe

    President and CEO of Arcutis

  • Simone Biles

    World champion gymnast partnered with Arcutis for brand campaign

Related articles

$ARQTHighAI 8/10

Arcutis reports trial data on infant eczema treatment candidate

Arcutis Biotherapeutics (ARQT) presented INTEGUMENT-INFANT trial data for ZORYVE cream 0.05% in treating infant atopic dermatitis. The study showed no serious adverse events, with 66.7% of infants reporting itch improvement within 4 hours. The cream is approved for children 2-5 years and is under FDA review for infants 3-24 months, with a decision expected by February 23, 2027.

$ARQTMedAI 8/10

TD Cowen raises Arcutis stock price target on Zoryve momentum

TD Cowen raised its price target for Arcutis Biotherapeutics (ARQT) to $40 from $35, citing strong Zoryve sales of $144M and raised 2026 guidance. Revenue grew 11% quarter-over-quarter and 45% year-over-year, with a 91% gross profit margin. The stock trades near its 52-week high at $34.05. Arcutis reported Q3 2026 revenue of $143.9M, beating estimates, but missed profit expectations.